GB2131293A - Composition containing dextran for use in medical treatment - Google Patents

Composition containing dextran for use in medical treatment Download PDF

Info

Publication number
GB2131293A
GB2131293A GB08234504A GB8234504A GB2131293A GB 2131293 A GB2131293 A GB 2131293A GB 08234504 A GB08234504 A GB 08234504A GB 8234504 A GB8234504 A GB 8234504A GB 2131293 A GB2131293 A GB 2131293A
Authority
GB
United Kingdom
Prior art keywords
composition
collagen
dextran
weight
gelatinous material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08234504A
Other versions
GB2131293B (en
Inventor
Roy Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB08234504A priority Critical patent/GB2131293B/en
Publication of GB2131293A publication Critical patent/GB2131293A/en
Application granted granted Critical
Publication of GB2131293B publication Critical patent/GB2131293B/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A pasty composition comprising collagen or other collagen-type gelatinous material, dextran and an aqueous saline solution or the like is useful as a dressing in the treatment of dry sockets following tooth extraction or for other medical purposes.

Description

SPECIFICATION Composition for use in medical treatment The present invention relates to a composition for use in medical treatment, particularly but not exclusively in dentistry as a dressing for treatment of dry sockets following tooth extraction.
In dentistry a not uncommon sequel to tooth extraction is the development of a dry socket. One to three days post-extraction there is partial or complete disintegration of the blood clot. Any remaining clot is heavily contaminated. Large areas of the lamina dura are necrotic and osteocyte lacunae are empty. The inflammatory process spreads to the surrounding marrow spaces and often to the periosteum. A heavy subepithelial inflammation is seen in the gingiva. Necrotic tissue is found in the marrow spaces closest to the alveolus. In the marrow space thrombosis, the presence of polymorphonuclear leukocytes and mononuclear cells present a picture of a localised acute or subacute osteomyelitis. Extensive osteoclastic activity is seen and the repair process is delayed.Granulation tissue starts to grow into the alveolus from the perforations in the lamina dura and the healing process progresses from the base of the socket.
In man, fibrinolytic alveolitis presents two problems: namely persistent pain and delayed healing.
At present many non-physiological dressings acting as a mechanical barrier and antiseptic are used with or without a curettage of the socket. They include obtundant materials such as eugenol or oil of cloves mixed into a paste with zinc oxide, or Whitehead's varnish (benzoin, storax, balsam of Tolu, iodoform, solvent ether) placed on ribbon gauze. More recently the dextran polymer Debrisan has been advocated, but its use in the mouth has presented isolation problems and patients are requested to return daily for a change of packing.
The present invention seeks to provide an improved dressing for this purpose.
According to the invention there is provided a composition useful as a dressing in medical treatment, comprising collagen-type gelatinous material, dextran and an aqueous solution of a physiologically harmless electrolyte.
Preferably the gelatinous material comprises collagen. The collagen may be of heterogeneous origin and may be soluble or insoluble or may be a mixture of soluble and insoluble material in any proportion. The use of a mixture of soluble and insoluble collagen in proportions by weight from 2:1 to 1 :2, especially about equal proportions, is particularly desirable. However, other gelatinous materials having a structure similar to that of collagen, namely polypeptide strands of molecularweight in the region of 105, may also be used.
The dextran to be used is a glucose polymer of chain-like structure and is obtainable in a variety of molecular weights. Preferably the material used has a molecular weight in the range 60,000 - 90,000, for example Dextran 70 with a molecular weight of 70,000.
The aqueous solution is preferably a saline solution for antiseptic purposes, but other electrolyte solutions which do not harm the patient may be used.
The composition may, if desired, contain other ingredients, for various purposes. For example, glycerol may be present to act as an emulsifier or lubricant.
For best results the composition is desirably applied in the form of a paste with sufficient of the aqueous solution to achieve the desired pasty consistency. Suitably about 45 - 50% by weight of the aqueous solution is used. The major proportion of the solid material should be the collagen-type, for example 75 - 90% by weight of the solid material, with the dextran suitably constituting 10 to 25% by weight of the solid material.
Particularly preferred compositions have the following constitution by weight: insoluble collagen 20-25% e.g. 22% soluble collagen 20-25% e.g. 22% dextran 5-10% e.g. 8% normal saline solution 45-50% e.g. 48% It will be appreciated that, although the composition used as a dressing will contain the aqueous electrolyte solution, the aqueous solution can be mixed with the other ingredients just before use, so that the invention also includes a composition comprising simply the collagen-type material and the dextran prior to addition of water.
In use to treat the dry socket condition in dentistry the composition is applied, suitably as a stiff paste, direct to the area of denuded bone. When used for this purpose it has the following advantages: 1. It relieves pain.
2. It is non-irritant to surrounding tissues.
3. It is incorporated or absorbed.
4. It is antiseptic.
5. It is a good bone sealant.
6. It is stable in oral fluids.
7. It does not undergo volume change when exposed to blood/saliva.
8. It is non-antigenic.
9. It is easy to apply.
10. Its use necessitates only a one visit treatment.
The composition may also be used outside dentistry for other medical purposes. For example, it would be of value in achieving haemostasis in bleeding bone, where it would act as a bone sealant, in orthopaedic, neuro-surgical or other related surgical fields. It would also have uses for patients with bleeding diathesis for local control of bleeding from bone. It would also act as a space filler in bony cavities when cyst-like lesions are removed in the above and similar surgical disciplines.
CLAIMS (Filed on 30.11.83) 1. A composition useful as a dressing in dental or other medical treatment, comprising collagen-type gelatinous material, dextran and an aqueous solution of a physiologically harmless electrolyte.
2. A composition as claimed in claim 1, wherein the ratio by weight of the gelatinous material to the dextran in the composition is from 3:1 to 9:1.
3. A composition as claimed in claim 1 or 2, wherein the composition is in the form of a paste containing 45 to 50% by weight of the aqueous solution.
4. A composition as claimed in any of claims 1 to 3, wherein the gelatinous material is collagen.
5. A composition as claimed in any of claims 1 to 4, wherein the collagen is a mixture of soluble collagen and insoluble collagen in a ratio by weight of from 1:2 to 2:1.
6. A composition as claimed in any of claims 1 to 5, wherein the dextran has a molecular weight of 60,000 to 90,000.
7. A composition as claimed in any of claims 1 to 6, which also contains glycerol as an emulsifier/ lubricant.
8. A composition as claimed in claim 1 and substantially as hereinbefore described.
9. A composition comprising collagen-type gelatinous material and dextran and being capable of forming a composition as claimed in any of claims 1 to 8 on addition of an aqueous solution of a physiologically harmless electrolyte.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (9)

**WARNING** start of CLMS field may overlap end of DESC **. The composition may also be used outside dentistry for other medical purposes. For example, it would be of value in achieving haemostasis in bleeding bone, where it would act as a bone sealant, in orthopaedic, neuro-surgical or other related surgical fields. It would also have uses for patients with bleeding diathesis for local control of bleeding from bone. It would also act as a space filler in bony cavities when cyst-like lesions are removed in the above and similar surgical disciplines. CLAIMS (Filed on 30.11.83)
1. A composition useful as a dressing in dental or other medical treatment, comprising collagen-type gelatinous material, dextran and an aqueous solution of a physiologically harmless electrolyte.
2. A composition as claimed in claim 1, wherein the ratio by weight of the gelatinous material to the dextran in the composition is from 3:1 to 9:1.
3. A composition as claimed in claim 1 or 2, wherein the composition is in the form of a paste containing 45 to 50% by weight of the aqueous solution.
4. A composition as claimed in any of claims 1 to 3, wherein the gelatinous material is collagen.
5. A composition as claimed in any of claims 1 to 4, wherein the collagen is a mixture of soluble collagen and insoluble collagen in a ratio by weight of from 1:2 to 2:1.
6. A composition as claimed in any of claims 1 to 5, wherein the dextran has a molecular weight of 60,000 to 90,000.
7. A composition as claimed in any of claims 1 to 6, which also contains glycerol as an emulsifier/ lubricant.
8. A composition as claimed in claim 1 and substantially as hereinbefore described.
9. A composition comprising collagen-type gelatinous material and dextran and being capable of forming a composition as claimed in any of claims 1 to 8 on addition of an aqueous solution of a physiologically harmless electrolyte.
GB08234504A 1982-12-03 1982-12-03 Composition containing dextran for use in medical treatment Expired GB2131293B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08234504A GB2131293B (en) 1982-12-03 1982-12-03 Composition containing dextran for use in medical treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08234504A GB2131293B (en) 1982-12-03 1982-12-03 Composition containing dextran for use in medical treatment

Publications (2)

Publication Number Publication Date
GB2131293A true GB2131293A (en) 1984-06-20
GB2131293B GB2131293B (en) 1986-03-05

Family

ID=10534718

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08234504A Expired GB2131293B (en) 1982-12-03 1982-12-03 Composition containing dextran for use in medical treatment

Country Status (1)

Country Link
GB (1) GB2131293B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224453A2 (en) * 1985-11-26 1987-06-03 Pierfrancesco Morganti Biologically active topical collagen support matrix: cosmetic and pharmaceutical uses and a process for its preparation
FR2591892A1 (en) * 1985-12-23 1987-06-26 Pf Medicament COLLAGEN ASSOCIATION / ACTIVEANTISEPTIC AND / OR ANTI-INFLAMMATORY PRINCIPLE AS COMPOSITION, PROCESS FOR PREPARING THE SAME AND USE THEREOF FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION
EP0246809A2 (en) * 1986-05-19 1987-11-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sustained-release pharmaceutical compositions
EP0250571A1 (en) * 1986-01-06 1988-01-07 Univ Melbourne Precipitation of collagen in tactoid form.
EP0572272A1 (en) * 1992-05-29 1993-12-01 JOHNSON & JOHNSON MEDICAL, INC. Absorbable bone sealant
US6280474B1 (en) 1997-01-09 2001-08-28 Neucoll, Inc. Devices for tissue repair and methods for preparation and use thereof
EP1241226A1 (en) * 2001-03-16 2002-09-18 Swiss Caps Rechte und Lizenzen AG Use of a polyol as a gelling agent for cold-water soluble gelatin gels. Films, articles and capsules formed therefrom

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224453A3 (en) * 1985-11-26 1988-10-26 Pierfrancesco Morganti Biologically active topical collagen support matrix: cosmetic and pharmaceutical uses and a process for its preparation
EP0224453A2 (en) * 1985-11-26 1987-06-03 Pierfrancesco Morganti Biologically active topical collagen support matrix: cosmetic and pharmaceutical uses and a process for its preparation
FR2591892A1 (en) * 1985-12-23 1987-06-26 Pf Medicament COLLAGEN ASSOCIATION / ACTIVEANTISEPTIC AND / OR ANTI-INFLAMMATORY PRINCIPLE AS COMPOSITION, PROCESS FOR PREPARING THE SAME AND USE THEREOF FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION
EP0233429A1 (en) * 1985-12-23 1987-08-26 Pierre Fabre Medicament Pharmaceutical composition containing a mixture of collagen and an antiseptic and/or anti-inflammatory effective substance and process for its manufacture
US4789662A (en) * 1985-12-23 1988-12-06 Pierre Fabre Medicament Method for the treatment of periodontal pockets with a composition comprising collagen and an antiseptic or anti-inflammatory substance
EP0250571A1 (en) * 1986-01-06 1988-01-07 Univ Melbourne Precipitation of collagen in tactoid form.
EP0250571A4 (en) * 1986-01-06 1988-08-17 Univ Melbourne Precipitation of collagen in tactoid form.
EP0246809A2 (en) * 1986-05-19 1987-11-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sustained-release pharmaceutical compositions
EP0246809A3 (en) * 1986-05-19 1988-01-13 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Sustained-release pharmaceutical compositions
EP0572272A1 (en) * 1992-05-29 1993-12-01 JOHNSON & JOHNSON MEDICAL, INC. Absorbable bone sealant
AU669519B2 (en) * 1992-05-29 1996-06-13 Johnson & Johnson Medical, Inc. Absorbable bone sealant
US6280474B1 (en) 1997-01-09 2001-08-28 Neucoll, Inc. Devices for tissue repair and methods for preparation and use thereof
EP1241226A1 (en) * 2001-03-16 2002-09-18 Swiss Caps Rechte und Lizenzen AG Use of a polyol as a gelling agent for cold-water soluble gelatin gels. Films, articles and capsules formed therefrom
WO2002074861A1 (en) * 2001-03-16 2002-09-26 Swiss Caps Rechte Und Lizenzen Ag Use of polyol as a gel former, composition for the production of films and moulded bodies, method for the production of a gelatine gel which is soluble in cold water and method for producing a capsule.

Also Published As

Publication number Publication date
GB2131293B (en) 1986-03-05

Similar Documents

Publication Publication Date Title
US5696101A (en) Oxidized cellulose and vitamin E blend for topical hemostatic applications
EP0390541A2 (en) Paste-like base and preparation
EP1206271A1 (en) Composition and method for enhancing wound healing
JP2007506505A (en) Bioabsorbable putty-like hemostatic implant
US10022411B2 (en) Hemostatic preparation containing an extract of golden moss
AU2010335066A1 (en) Topical oral gel formulations for dental use
EP0472575A1 (en) Improvements in or relating to pharmaceutical preparations
DE202016102375U1 (en) Dental agent based on hyaluronan and octenidine dihydrochloride
JP2023516514A (en) Medical adhesive, its preparation method, and its use
GB2131293A (en) Composition containing dextran for use in medical treatment
CA2765271C (en) Silver hydrosol, dental application and other uses thereof
EP0191086A1 (en) Bone-replacing material
AU612387B2 (en) Pharmaceutical compositions promoting the wound healing and process for preparing same
CH643732A5 (en) Aid for covering and/or filling bone defects and process for the production thereof
WO2020249711A1 (en) Injectable aqueous implant formulation containing ascorbic acid
RU2074702C1 (en) Material for osseous tissue recovery
JPH09169612A (en) Dental root canal filler composition
Mitchell Treatment of fibrinolytic alveolitis by a collagen paste (formula K): A preliminary report
RU2653480C1 (en) Composition for stimulation of regeneration in defects of bone jaw tissue
JPH03261643A (en) Curable composition
Carroll et al. The histologic effect of topically applied acetylsalicylic acid on bone healing in rats
de OLIVEIRA RODRIGUES et al. “Bone Wax” implantation into Dental Sockets Clinical and Histological Evaluation in Patients
RU2242987C1 (en) Hemostatic preparation
RU2088240C1 (en) Method of preparing the preparation for reparative osteogenesis activation
SK15212000A3 (en) A preparation consisting of calcium hydroxide, a dihydric or polyvalent alcohol, a fatty oil of vegetable or animal origin, and its use for regenerating collagen

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19981203